Ehaweb - ehaweb.org - EHA Articles
General Information:
Latest News:
Targeting the B-cell Receptor in Aggressive B-cell Lymphomas 14 Jun 2013 | 02:25 pm
In collaboration with Dr. Lou Staudt, Pharmacyclics and associate investigators, we performed a clinical trial of a very potent inhibitor of Bruton Tyrosine Kinase (BTK) called ibrutinib. Inhibition ...
Pomalidomide prolongs survival in refractory myeloma patients 14 Jun 2013 | 02:25 pm
MM-003 is a large, multi-centre phase 3 study that assessed the efficacy and safety of a new drug, Pomalidomide (POM) in combination with low-dose dexamethasone (POM+LoDex) and compared this combinati...
DARATUMUMAB, a CD38 Monoclonal Antibody Study in Advanced Multiple Myeloma – an Open-Label, Dose Escalation Followed by Open-Label Extension in a Sing... 14 Jun 2013 | 02:25 pm
Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases. Daratumumab has received Fast...
Mini-hormone fights iron 14 Jun 2013 | 02:25 pm
Iron overload commonly leads to organ damage and even death. Currently available treatments for iron overload are burdensome or cause side effects. The cause of iron overload in diseases such as her...
TARGETING THE JAK-STAT PATHWAY IN MALIGNANT AND NON-MALIGNANT CELLS IN MYELOPROLIFERATIVE NEOPLASMS 14 Jun 2013 | 02:24 pm
Myeloproliferative neoplasms (MPN) are clonal blood disorders characterized by excessive production of mature blood cells. Patients present with large spleens, systemic symptoms, and high levels of ci...
Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-ex... 14 Jun 2013 | 02:24 pm
CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments. It has been an unresolved quest...
Position of EHA on Access to Medicines 12 Jun 2013 | 07:34 pm
There are many factors that compromise patient access to medicine. First and foremost, for a drug to be available, one has to be developed. Access to an effective drug therefore relies on innovative r...
Position of EHA on the Harmonization of Training and Education in Europe 12 Jun 2013 | 07:34 pm
The challenge Education and training are largely national competencies. Except for the EU’s competency to encourage and support cooperation, it is at the level of the Member State where policies abou...
Position of EHA on Research Funding 12 Jun 2013 | 07:33 pm
The challenge The cost of biomedical research is great, but the cost of disease is immense. An ageing population and expensive innovations in medicine put an increasing burden on already stressed hea...
Position of EHA on Clinical Trials 12 Jun 2013 | 07:33 pm
The challenge In Europe, the number of clinical trials is steadily decreasing. From 2007 to 2010, their number has decreased by some 20 percent from 5,028 to 4,193. Concurrently, the number of trial ...
